Promising data of an anti-infective therapeutic to treat Cystic Fibrosis-associated lung infections was presented in the 28th Annual North American Cystic Fibrosis Conference, held last week in Atlanta, GA, by N8 Respiratory, LLC. showing the efficacy of its lead compound CSA-13 as an Continue reading CF Community Takes Notice of New Antimicrobial Biofilm That Fights Psuedomonas Aeruginosa
Company Completes Enrollment in Phase 2 Clinical Trial
Austin, TX – October 6, 2014 – Savara Pharmaceuticals announced today that it closed a $10 million bridge financing round to support the development of AeroVanc, the first inhaled antibiotic Continue reading Savara Pharmaceuticals Raises $10 Million to Advance AeroVanc for MRSA Lung Infection in People with Cystic Fibrosis
What can be done for sinuses that seem to get infected quite frequently? Oral antibiotics, IV antibiotics, nasal lavage, inhalations and lions, tigers and bears, oh my.
But seriously, aside from the easiest, oral antibiotics, which can wreak havoc on the rest of our Continue reading Sinus Solutions? By Andrea Eisenman
Raleigh biotechnology company Agile Sciences has landed a $1.5 million National Institutes of Health grant to help develop its cystic fibrosis therapy derived from sea sponges.
Agile was spun out of North Carolina State University with the help of a $30,000 startup loan from Continue reading Agile Sciences lands $1.5M NIH grant for cystic fribosis therapy
Artilysins constitute a novel class of efficient enzyme-based antibacterials. Specifically, they covalently combine a bacteriophage-encoded endolysin, which degrades the peptidoglycan, with a targeting peptide that transports the endolysin through the outer membrane of Gram-negative Continue reading Art-175 Is a Highly Efficient Antibacterial against Multidrug-Resistant Strains and Persisters of Pseudomonas aeruginosa.
Following the recent success of a phase 3b clinical trial for Aztreonam in cystic fibrosis (CF) patients with Burkholderia infections, Gilead Sciences, Inc., a research-based biopharmaceutical company engaged in CF drug discovery and development, completed another phase 3 clinical trial Continue reading Gilead’s AZLI Therapy For Treatment Of PALS In Cystic Fibrosis Deemed Safe, Effective In Recent Study
A once-daily inhaled antibiotic appeared to offer long-term benefits in cystic fibrosis (CF) patients with Pseudomonas aeruginosa infection, researchers said here.
In an extension of a trial that compared investigational liposomal amikacin for inhalation (Arikace) Continue reading Cystic Fibrosis: Once-A-Day Antibiotic Durable
– Data Demonstrate Positive Trends in Lung Function and Pulmonary Exacerbations –
SOUTH PLAINFIELD, N.J., May 16, 2014 /PRNewswire/ — PTC Therapeutics, Inc. PTCT -2.85% today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation Continue reading Ataluren Phase 3 Trial Results in Nonsense Mutation Cystic Fibrosis Published in The Lancet Respiratory Medicine
Gentamicin belongs to the amino glycoside class of antibiotics and is used to treat mostly gram negative bacterial infections, including severe ones like pyelonephritis, biliary sepsis, endocarditis, and cystic fibrosis among others. It is a bactericidal Continue reading Hearing Loss From Popular Cystic Fibrosis Antibiotic Could Be Treated With Vitamin Supplements
A Phase 2 clinical trial to evaluate the safety and efficacy of an
inhaled anti-MRSA antibiotic is enrolling now.
MRSA + CF
The prevalence of MRSA lung infection in cystic fibrosis (CF) patients has risen in the past decade, currently at 27% in the U.S. Recent publications indicate that chronic Continue reading Attention CF Patients With Persistent MRSA Lung Infection